Published in Gene Therapy Weekly, June 15th, 2006
Study 1: According to a study from Japan, cancer vaccine therapy improved using genetically modified dendritic cells (DCs) expressing tumor-associated antigen.
"The T-helper 1 (Th1) immune reaction is most important in DC-based immunotherapy. Interleukin 12 (IL-12) and granulocyte macrophage colony-stimulating factor (GM-CSF) play a pivotal role in inducing Th1 and cytotoxic T lymphocyte (CTL) responses.
"In this study, DCs expressing the natural tumor antigen gp70 of BALB/c-derived CT26 were adenovirally transduced with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-06-15)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.